1. Cilostazol decreases total atrial conduction time in patients with peripheral artery disease.
- Author
-
Alizade, E, Şahin, M, Şimşek, Z, Açar, G, Bulut, M, Güler, A, Avcı, A, Kalkan, ME, Pala, S, Akçakoyun, M, and Esen, AM
- Subjects
- *
ATRIAL fibrillation prevention , *ACADEMIC medical centers , *ECHOCARDIOGRAPHY , *PERIPHERAL vascular diseases , *STATISTICS , *T-test (Statistics) , *TETRAZOLES , *DATA analysis , *DATA analysis software , *DESCRIPTIVE statistics , *PHARMACODYNAMICS - Abstract
Objective: Total atrial conduction time (TACT) is the most important parameter in predicting the development of newonset atrial fibrillation. We investigated the effect of cilostazol therapy on TACT in patients with peripheral artery disease. Methods: Thirty patients with peripheral artery disease were treated with cilostazol (200 mg/day) for 6 months. The baseline echocardiographic total atrial conduction time parameter was compared with the 6-month follow-up. Results: The TACT duration was decreased in all patients compared with the baseline after therapy (121.8 ± 19.3 vs. 109.1 ± 15.9 milliseconds, p<0.001). However, left atrial (LA) diameter was not changed with the therapy. The reduction of TACT duration was correlated with the increase in mitral E wave velocity/mitral A wave velocity ratio (r=-0.48, p<0.003). Conclusion: Our results showed that 200 mg cilostazol treatment decreased TACT duration in patients with peripheral artery disease, which may also prevent the development and/or recurrence of atrial fibrillation (AF). [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF